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Available online 30 March 2019FMThas gained enormousmomentum in the treatment of acute inﬂammatory and infectious diseases. Despite an
encouraging safety proﬁle, FMT has been met with caution in the oncological setting due to perceived infectious
risks in immunocompromised patients. Theoretical risks aside, the application of FMT in oncology may stand to
beneﬁt patients, via modulation of treatment efﬁcacy and the mitigation of treatment complications. Here, we
summarize most recent safety data of FMT in immunocompromised cohorts, including people with cancer,
highlighting that FMTmay actually provide protection against bacterial translocation via introduction of a diverse
microbiome and restoration of epithelial defenses.We alsodiscuss the emerging translational applications of FMT
within supportive oncology, including theprevention and treatment of graft vs. host disease and sepsis, treatment
of immunotherapy-induced colitis and restoration of the gut microbiome in survivors of childhood cancer.
© 2019 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Fecal microbiota transplantation (FMT) involves the administration
of a fecal suspension into the digestive tract of an individual, with
the aim of treating or preventing disease via manipulation of the
microbiome [1]. FMT was ﬁrst reported as a novel treatment of
pseudomembranous enterocolitis in 1958. Since that time, the efﬁcacy
of FMT for recurrent or refractory Clostridium difﬁcile infection (CDI)
has been established in multiple randomized controlled trials and its
use in this setting is supported by society guidelines [1–3]. FMT success-
fully treats recurrent or refractory CDI in N90% of cases, compared with
cure rates of 26–30% with the previous standard of care, vancomycin
[4,5]. A burgeoning understanding of the gut microbiome coupled
with the success of FMT in treating CDI has garneredwidespread enthu-
siasm for the use of FMT across of range of diseases, with several trials
demonstrating the efﬁcacy of FMT for the induction of remission of ul-
cerative colitis [6]. However, a novel application of FMT resides within
oncology, with experimental FMT currently under investigation for its
ability to modulate treatment efﬁcacy and mitigate serious complica-
tions of treatment including sepsis and graft versus host disease
(GvHD).
Despite a growing scientiﬁc rationale and emerging clinical potential
for FMT use in oncology, it has been met with caution due to the per-
ceived risk of bacterial translocation and infection in potentially immu-
nocompromised individuals. This parallels current investigation of FMT
for the treatment of CDI, with most clinical trials excluding immuno-
compromised patients. These recommendations are also echoed in clin-
ical practice guidelines developed for the treatment of CDI in children
with hematological cancers [7], and parallel recent recommendations
from the Food and Drug Administration/Center for Biologics Evaluation
and Research cautioning against FMT in immunocompromised cohorts
[8]. While these recommendations are intended to avoid harm, they
are based primarily on expert opinion without supportive evidence.
The limited evidence currently available suggests that FMT holds no ad-
ditional risk in immunocompromised individuals [8] and as such, coor-
dinated and interdisciplinary efforts to investigate its safety and efﬁcacy
in various indications within oncology are warranted.
This review aims to provide an overview of the current mechanistic
understanding of FMT and the emerging applications in supportive on-
cology with particular emphasis on the adverse events or safety issues
regarding reported for experimental FMT in immunocompromised
individuals.
2. Proposed mechanism(s) of action of FMT in CDI
To date, themechanisms of FMT have been primarily investigated in
the setting of CDI. Fundamental research into the underlying mecha-
nism(s) for FMT in this setting identify two possible avenues by which
FMT is effective: 1) direct interaction with the gut microbiota and
2) modulation of the host's intestinal physiology and immune capacity
[9,10].
2.1. FMT and the gut microbiota
CDI is typically induced by exposure to antibiotics, which deplete the
indigenous gut ﬂora and leaves an ecological void into which Clostrid-
ium difﬁcilemay proliferate. Disruption of the host's microbiota allows
opportunistic and resistant microbes greater access to intestinal nutri-
ents. This is nicely illustrated in the biosynthesis of sialic acid, a
carbon-backboned monosaccharide ubiquitously expressed within gly-
coproteins and glycolipids [11]. Certain commensal bacteria, including
Bacteroides thetaiotaomicron, are able to liberate sialic acid from mucin
glycoproteins, but are unable to break it down completely [10]. In con-
trast, Clostridium difﬁcile possesses the ability to catabolize sialic acid,
utilizing it as an energy source. Similarly, microorganisms also liberate
monomeric glucose and N-acetylglucosamine, which then becomemore accessible to Clostridium difﬁcile when indigenous microbiota are
absent or suppressed. As such, a potential factor in the efﬁcacy of FMT
for CDI is its ability to reintroduce microbial competition, recolonizing
the microbial niches that Clostridium difﬁcilewould otherwise exploit.
Depletion of microbial diversity also reduces the host's natural de-
fenses against pathogenic bacteria including antimicrobial peptides
and bile acids, both of which effectively control Clostridium difﬁcile ex-
pansion and spore formation. Bactericidal peptides such as thuricin
CD, produced by Bacillus thuringiensis, and nisin, produced by Gram-
positive bacteria, both have high potency against certain Gram-
positive microbes including Clostridium difﬁcile.10 Similarly, secondary
bile salts, generated via bacterial-dependent deconjugation of taurine
and glycine, are almost absent in people with recurrent CDI as bacteria
with this functional capacity are commonly reduced by antibiotics
[12]. Of particular relevance is the loss of Clostridium scindens, a 7α-
dehydroxylating gut microbe, which encodes for the bai operon and is
responsible conversion of primary bile acids into secondary bile acids
[13]. Importantly, these secondary bile acids produce deoxycholic and
lithocholic acids, both of which have shown to inhibit germination of
Clostridium difﬁcile spores [14]. In line with this understanding, it has
been recently demonstrated that successful FMT for recurrent CDI is as-
sociated with increased signaling in the bile acid-farneoid X receptor-
ﬁbroblast growth factor pathway [15].
2.2. FMT and host immunity
It is well demonstrated that a bidirectional, symbiotic relationship
exists between the host and its resident microbes, with continuous sig-
naling from the indigenous microbiota required to maintain a healthy
gut barrier function and balancedmucosal immunity. Numerous factors
including mucus, tight junctions and antimicrobial peptides, maintain
appropriate compartmentalization of the microbiota in the intestinal
lumen, regulating their interaction with the underlying mucosal im-
mune system. Antibiotics are well demonstrated to disrupt almost all
aspects of this defense, weakening the intestinal barrier and disrupting
homeostatic control of paracellular permeability [16]. Once in contact
with the epithelia, Clostridium difﬁcile toxins disrupt intestinal tight
junctions and promote apoptotic death of colonocytes [17], resulting
in increased permeability of the epithelial barrier and interaction of
toxins and Clostridium difﬁcile pathogen-associated molecular patterns
(PAMPs) with resident mucosal immune cells via toll-like receptors
(TLRs).Whilst excessive activation of certain TLRs, such as TLR4, is asso-
ciatedwith aberrant immune signaling, activation of other TLR subtypes
is associated with dampened immune responses. For example, stimula-
tion of TLR2 via binding of cell wall components of primarily gram-
positivemicrobes, increases interleukin-10 (IL-10) production and is as-
sociatedwith enhanced intestinal barrier function observed in vitro and
in vivo [18,19].As such, the efﬁcacy of FMT in treating CDI is also likely to
reﬂect its ability to restore TLR signaling, thus repairing intestinal bar-
rier defenses and controlling exuberant immune responses. Comparable
immunomodulatory effects have also been proposed to underpin the
emerging efﬁcacy of FMT in IBD, equilibrating aberrant immune signal-
ing towards the indigenous microbiota [20].
3. General safety considerations of FMT
FMT has demonstrated an excellent overall safety proﬁle, with few
and primarily mild adverse events reported in the short term. However,
the majority of FMT studies that have been reported in the literature
have occurred in the last 5–10 years and as such, long-term safety
data is lacking. Despite the encouraging safety record of FMT, there is
risk of disease transmission from thedonor to recipient via stool, includ-
ing infection, as well as immunological and metabolic disorders [21].
Transmission of an obese phenotype has been demonstrated in animal
studies and the possible transmission of a microbiome that drives obe-
sity has been reported in a single human case report [22]. However, it
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factors that may have explained the weight gain seen in this patient.
Rigorous and standardized donor FMT screening protocols are required,
which diminish but do not entirely eliminate risk of disease transmis-
sion. Although the risks associated with autologous FMT are lower
(where pre-emptive collection and storage of a patient's own stool is
undertaken so that it may be readministered at a time of need), appro-
priate safety assessments, processing and storage is essential.
In a large systematic review of adverse events (AEs) for FMT (N =
1089 patients), it was reported that the majority of AEs were gastroin-
testinal in nature, including abdominal discomfort, acute diarrhea, tran-
sient fever, nausea, vomiting and constipation [23]. The overall
incidence of AEswas 28·5%. Authors attributed AEs to a variety of causal
factors, with only ﬁve categories of AEs deﬁnitely linked with FMT. AEs
deﬁnitely linked to FMT were a sore throat, rhinorrhea (both following
upper GI administration), aminormucosal tear and a bowel perforation
(both from colonoscopically administered FMT). Thirty-eight kinds of
AEs, probably related to FMT, were reported in 35 articles andwere con-
sidered the result of temporary systemic immune responses to the
transplanted bacteria.
Authors reported that the mode of delivery was a key risk factor for
FMT-related AEs, with endoscopic manipulation associated with nasal
stufﬁness, a sore throat, rhinorrhea and upper gastrointestinal hemor-
rhage. Abdominal discomfort was reported to be more frequent with
upper gastrointestinal delivery. Serious adverse events (SAEs) were re-
ported in 9·2% of patients including infection, disease relapse and CDI,
with a mortality rate of 3·5%. In both cases of FMT-related mortality,
death resulted from aspiration pneumonia in immunocompromised in-
dividuals (outlined below).
4. Safety proﬁle of FMT for CDI in immunocompromised recipients
FMT for the treatment of immunocompromised patients has been
met with caution due to the perceived risk of bacterial translocation
and sepsis. However, systematic review data suggest that FMT for the
treatment of CDI in immunocompromised patients is feasible and safe,
describing similar rates of serious adverse events to immunocompetent
patients [24,25]. A systematic review identiﬁed 44 articles in which
FMT had been performed for CDI in 303 immunosuppressed patients.
A patient was deﬁned as immunocompromised if receiving immuno-
suppressive agents (including but not limited to mTOR inhibitors, cal-
cineurin inhibitors, anti-TNF agents, other biologic agents, high dose
steroids N20 mg/day or ≥ 1 mg/kg for N14 days), or diagnosed with
HIV infection (regardless of CD4 count), acquired immune deﬁciency
syndrome (AIDS), inherited or primary immunodeﬁciency syndromes,
hematologic malignancy or solid tumor (active with treatment in past
3 months or in remission for b5 years), solid organ transplant, and/or
bone marrow transplant. FMT was primarily delivered via colonoscopy
(76%), with the remaining delivered via ingestible capsule/nasal tube/
endoscopy or retention enema. Reported efﬁcacy for CDI was 87·7%
from a single FMT, which increased to 93% after repeated FMTs,
paralleling efﬁcacy rates reported in immunocompetent cohorts.
Two deathswere reported in the immunocompromised FMT cohort,
both related to aspiration pneumonia. The ﬁrst patient aspirated during
sedated endoscopic FMT delivery to the duodenum [26] and the other
aspirated during the anesthetic for colonoscopic FMT [8]. Other re-
ported adverse events include 2 colectomies due to worsening CDI, 5
episodes of bacteremia or infection, 10 subsequent hospitalizations, 7
otherwise unspeciﬁed life-threatening complications, and 7 ﬂares of
IBD, as well as generalized abdominal discomfort. The rate of reported
complications, as well as the nature of AEs, were comparable to those
of immunocompetent cohorts, suggesting that FMT confers no addi-
tional risk in immunocompromised patients. However, it must be
noted that limited long-term data exists for both immunocompetent
and immunocompromised cohorts, and the possibility of late complica-
tions remains unclear. There is an observation trial currently underwayaiming to collect long-term data for 10 years post FMT (NCT03325855),
and FMT registries are planned.
4.1. Shifting the perception of risk in immunocompromised cohorts
Despite the growing body of evidence demonstrating comparable
safety proﬁles for FMT in immunocompetent and immunocompro-
mised cohorts, there remains a perception that FMT may be unsafe in
these patients. While larger cohorts of patients are needed to establish
whether FMT is safe in immunocompromised patients, there are theo-
retical reasons why FMTmay actually reduce the risk of bacterial trans-
location and ensuing infection in immunocompromised individuals.
A complex and diverse microbiota is able to resist colonization by
pathogenic organisms, through regulation of the intestinal barrier, pro-
motion of epithelial repair and proliferation, mucus production and the
generation of antimicrobial peptides (Fig. 1). It has been demonstrated
that disruption of themicrobiota, induced by antibiotics or othermicro-
bial insults, is a key risk factor for infectious complications [27]. Admin-
istration of antibiotics prior to pathogen exposure results in a marked
increase in colonization and systemic uptake of these pathogens [28];
a phenomenon clearly underpinning the pathobiology of CDI. Similarly,
it has been demonstrated that ﬂuoroquinolone administration in
allogeneic-stem cell transplant (allo-SCT) recipients, results in domina-
tion of themicrobiota by aerobic gram-negative bacteria, which is asso-
ciated with subsequent gram-negative bacteremia [29]. Most recently,
dominant microbial phyla in allo-SCT recipients have been shown to
predict subsequent bacteremia, suggesting that dominant bacteria are
more likely to translocate and drive infectious complications [30]. Sim-
ilar associations have been demonstrated in the longitudinal analysis of
themicrobiome in hematopoietic-SCT (HSCT) recipients, in whom a re-
duction in obligate anaerobes is associatedwith expansion and domina-
tion of pathogenic microbes (including viridans-group streptococci and
vancomycin-resistant enterococcus) [31]. As such, delivering a diverse
microbiome to immunocompromised patients may in fact decrease
the risk of infectious complications and efforts to better characterize
the safety of FMT in these cohorts are therefore warranted, albeit with
caution.
5. Emerging applications of FMT in supportive oncology
People undergoing cancer therapy,many ofwhomare immunocom-
promised, are at risk of microbiome disruption due to anti-cancer ther-
apy and antibiotics. It is well demonstrated that numerous anti-cancer
agents signiﬁcantly disrupt the intestinal microbiota with decreases in
microbial diversity and a shift towards a gram-negative enterotype
[32]. Dominance of opportunistic gram-negative microbes, combined
with the direct cytotoxic damage to the intestinal lining (mucositis),
predispose patients to secondary infections and various complications,
including infection and, in the case of allo-HSCT, GvHD. As such, the po-
tential applications ofmicrobial intervention in supportive oncology can
be broadly categorized into the prevention/management of 1) acute
toxicities, and 2) secondary complications (Table 1).
5.1. Gastrointestinal toxicity/mucositis
Gastrointestinal (GI) toxicity, manifesting as diarrhea, remains one
of the most common and clinically signiﬁcant complications of all
anti-cancer therapies. Prior to the widespread availability of genomic
technology, GI toxicity was understood to incorporate both direct cyto-
toxic and indirect inﬂammatory-based mechanisms leading to epithe-
lial injury and gut dysfunction. Bacterial colonization at the injured
sites was documented and linked with secondary complications such
as bacteremia and sepsis. Technological advances have facilitated a
clearer mechanistic appreciation of the contribution of gut microbiota
to GI toxicity in anti-cancer therapy [33,34], however dissecting the
causative role for the microbiome in GI toxicity remains challenging.
Fig. 1. Potential mechanisms by which FMT may be beneﬁcial to those undergoing cancer therapy. Delivering a diverse microbiome serves to promote microbial competition, thus
controlling pathogen expansion and reducing the risk of infectious complications. Similarly, FMT has been shown to restore short chain fatty acid proﬁles, thus aiding epithelial repair
and intestinal homeostasis. FMT may also be used to promote a unique microbial phenotype known to induce preferable treatment responses; an approach increasingly investigated
for immunotherapy-colitis and efﬁcacy. Promoting microbial diversity via FMT is also likely to enhance natural barrier defenses, including anti-microbial peptides, tight junction
assembly/integrity, mucus production and epithelial proliferation. These hold great promise in promoting recovery from acute mucosal injury and preventing bacterial translocation;
each of which are key initiating factors in GvHD development. FMT efﬁcacy is also considered to occur via immunomodulating, promoting TLR equilibrium and dampening aberrant
inﬂammatory signaling.
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icity exacerbates the pathobiology of GI toxicity [34] via direct effects on
drug metabolism, modulation of the host immune system and disrup-
tion of the intestinal barrier. Furthermore, it is becoming increasingly
clear that an individual's unique microbiome is critical in shaping their
response to treatment [35]. As such, efforts to modulate an individual's
pre-treatment microbiome or preserve microbial diversity after treat-
ment are explored.
The identiﬁcation of cancer therapy-inducedmicrobiome disruption
prompted the investigation of probiotic therapies to prevent and treat
the symptoms of GI toxicity. Despite strong preclinical support in ani-
mal models [36–38], the efﬁcacy of probiotic formulations in humans
has been underwhelming. In fact, a recent meta-analysis reported no
beneﬁt for probiotics in GI toxicity prevention [39]. Currently available
probiotics lack the density and complexity to compete with indigenous
microbiota and are not rationally designed to fulﬁl speciﬁc therapeutic
roles. Lack of probiotic efﬁcacy is multifactorial, and reﬂective of vari-
able probiotic formulations and doses, variations in cancer treatment
schedules and the lack of diversity in currently available probiotic prep-
arations. As such, FMT represents a far more attractive alternative to
probiotics, given its ability to deliver a diversemicrobiome with greater
bacterial load, as well as the capacity to collect, bank and readminister
autologous fecal samples.
The only study to investigate FMT in GI toxicity management was
performed in mice following 5-ﬂuorouracil (5-FU) treatment (Table 2)
[40]. Le Bastard et al., (2018) reported that autologous FMT (200 μL sus-
pension at 5 g feces/1 mL PBS, delivered by oral gavage for 3 days) was
able to restore microbial diversity following exposure to 5-FU and anti-
biotics. However functional endpoints (e.g. diarrhea/weight loss) were
not reported and as such, the translational relevance of this study is lim-
ited. These results do however illustrate some important practical
points regarding FMT in supportive cancer care. Firstly, this study dem-
onstrates that chemotherapy exposure does not inﬂuence FMT durabil-
ity in mice, with taxonomic order restored following FMT. This was
despite FMT being delivered the day after cessation of antibiotics and5-FU, and coinciding with the time period where cytotoxicity, mucosal
injury and diarrhea are likely to be highest. These results echo the ﬁnd-
ings from Suez et al., (2018) showing a single autologous FMT in
humans was sufﬁcient to restore microbial diversity after antibiotic
exposure [41]. In fact, authors reported superior efﬁcacy to probiotics,
providing an excellent rationale to further investigate FMT as an adjunc-
tive supportive care measure.5.2. Immunotherapy colitis
A relatively newproblem in supportive oncology is themanagement
and prevention of severe colitis induced by newly developed immuno-
therapies. Treatments with immunotherapies targeting cytotoxic T-
lymphocyte-associated antigen4 (CTLA-4), programmed cell death pro-
tein 1 (PD-1), and programmed cell death ligand 1 (PD-L1) are associ-
ated with increased T-cell activation and effective antitumor immune
responses in a subset of ill-deﬁned patients [42]. However, these agents
carry a risk of severe colitis. Certain bacterial signatures have been
shown to associate with differential responses to immunotherapies
[42,43], both in terms of treatment efﬁcacy and toxicity. Additionally,
modulation of the gut microbiota via FMT from patients has been
shown to alter antitumor immunity and response to immunotherapy
in gnotobiotic mice (Table 2) [44]. These ﬁndings have now prompted
investigation of FMT as a therapeutic option for refractory
immunotherapy-induced colitis [45].
In 2018, the ﬁrst case series of immune checkpoint inhibitor-
associated colitis successfully treated with FMT was published [45].
Data, from the treatment of two individuals, highlight the ability of
donor FMT (50 g, delivered by colonoscopy) to restore microbial diver-
sity and induce complete resolution of clinical symptoms. Following
FMT, there was a substantial reduction in CD8+ T-cell density with a
concomitant increase in mucosal CD4+ FoxP3+ in one of the partici-
pants, offering a potential mechanism through which FMT could abro-
gate immunotherapy-associated toxicity (Table 2). A phase 1 trial is
Table 1





GI toxicity is associated with microbial disruption characterized by a loss
of overall species diversity and shift towards a gram-negative
enterotype.
Although causal relationship remains unclear, interventions targeting
the microbiota have proven efﬁcacious in various preclinical models,
with varying translational success.
Personalized donor or synthetic FMT to prophylactically enhance
outcomes; requires characterization of optimal microbial phenotypes
associated with treatment outcome in unique oncological settings.
Therapeutic FMT (autologous or donor) to
1) manage acute diarrhea,
2) promote recovery of microbiota and thus mitigate toxicity in




A growing evidence base shows stark differences in the microbial
composition of patients who develop colitis compared to those that do
not. Inconsistencies lie in the microbial phenotype linked with optimal
outcomes.
Prophylactic FMT to prevent colitis by modulating microbiota to a
composition associated with optimal toxicity proﬁles.
Therapeutic FMT to treat chronic immunotherapy-induced colitis.
Cognitive impairment A growing body of data now implicates the gut-brain axis in
neurocognitive function, with anecdotal evidence suggesting the
microbiome is critical in chemotherapy-induced neuroinﬂammation.
GI complications often occur in comparable patient cohorts as
neurocognitive impairment, indicating common underlying
mechanisms.
Probiotics and dietary interventions aimed at modulating the microbiota
have been shown to be effective in mitigating cognitive impairment in
other indications.
Assuming a ‘healthy’ microbiome at baseline, autologous FMT to
maintain individual's indigenous microbes and prevent
neuroinﬂammation via modulation of the gut-brain axis.
In cases where baseline microbiome composition is compromised, donor
FMT may be used prophylactically or therapeutically.
Secondary complication
prevention Infection
Pathogen dominance, bacterial translocation and blood stream infection
are more prevalent when the microbiota is compromised.
Antibiotics and GI toxicity are both risk factor for blood stream
infections in oncology cohorts with the microbiome composition able to
predict subsequent infections.
A diverse microbiome enhances natural defenses against bacterial
translocation and pathogen expansion.
Autologous or donor FMT to maintain microbial diversity throughout
treatment to prevent infectious complications via enhancing defenses
(intestinal barrier function, mucus production, antimicrobial peptides,
bile acid metabolism) and promoting colonization resistance.
Graft versus host disease Species diversity following conditioning chemotherapy predicts GvDH
in allo-SCT recipients.
Prophylactic FMT to maintain or restore microbial diversity thus
preventing mucosal injury and bacterial translocation; both of which are
critical in initiation of GvHD.




Chronic deﬁcits are observed in the microbiota of survivors of childhood
cancer.
Many of the late effect experienced by survivors have been linked with
the microbiome (e.g. metabolic syndrome).
Autologous FMT to restore individual's baseline microbiota composition
and prevent late effects associated with chronic microbial disruption.
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phylactic, adjunct supportive care measure (NCT03772899).5.3. Graft versus host disease and blood stream infections
In addition to the direct beneﬁts FMT may yield for acute GI injury
(mucositis and colitis), restoring the injured microbiota after the cessa-
tion of active cancer therapy may also offer a novel method of
preventing secondary complications (Fig. 2). It is clear that acutemicro-
bial disruption during cancer therapy predisposes to a number of sec-
ondary complications. Of particular importance is its potential
application in the prevention of blood stream infection [46] and GvHD
[47]; both ofwhich remain signiﬁcant causes ofmorbidity andmortality
in people undergoing cancer therapy. Whilst FMT for the prevention
and management of these complications lacks rigorous and controlled
clinical investigation, there is a growing body of data to support its po-
tential use. For example, intraduodenal donor FMT, performed in 20 pa-
tients (40% of whom were neutropenic), has been shown to be safe,
whilst also aiding in the eradication of antibiotic-resistant bacteria in
people with blood disorders (Table 2) [48]. Similarly, donor FMT (ad-
ministered by rectal enema or nasogastric tube) was shown to safely
eradicate multidrug-resistant bacteria in allo-SCT recipients, with 70%
of patients showing full decolonization. Whilst encouraging, conclu-
sions regarding the safety and efﬁcacy of FMT in this study must be
done so with caution due to the low sample size (N=10) and inconsis-
tencies in the timing and delivery of FMT [49].Similarly, a recent case study has shown donor FMT is able to treat
acute intestinal steroid-refractory and -dependentGvHD,with 3 of 4 pa-
tients showing complete resolution (Table 2) [50]. The same group has
also reported the feasibility of delivering encapsulated FMT for GvHD
treatment in a single case report [51]. This was further supported in an-
other pilot study (N=8) inwhich donor FMT (delivered via nasogastric
tube) induced a reparative effect onmicrobiota composition, increasing
diversity and elevating the abundance of Bacteroidetes, Bacteroidaceae,
Ruminococcaeae and Desulfovibrionaceae. This was accompanied by a
decrease in stool volume, reductions in abdominal pain and clinical res-
olution (termed “cure” in this study) in 50% of patients [52]. Of the re-
maining 4 patients, one showed an improvement in symptoms,
another was considered remissive and two relapsed. Whilst these
results are encouraging, these studies are underpowered, aiming to
simply investigate feasibility in small patient cohorts. Randomized
control trials are now warranted, and are underway (NCT02269150;
NCT03359980; NCT03492502; NCT03549676; NCT03720392).5.4. Promoting health in survivors of childhood cancer
The plausible beneﬁts of FMT in adjunctive oncology are similar for
children as adults and should, in cases where it permits, be investigated
in parallel. Guidelines for the management of CDI in children currently
recommend against the use of FMT due to perceived infection risks
[7]. This largely reﬂects the exclusion of children from FMT trials, and
a consequent paucity of data. However, data from case studies do
s-
Table 2
Preclinical and clinical studies of FMT in supportive oncology.
Indication Study type and
description










(1 g/L days 1–7) and 5-FU
chemotherapy (150 mg/kg
day 8) used to mimic
oncology setting
Pellets from untreated mice Pellets resuspended in PBS (1
pellet/1 mL PBS); pellets were
pooled from multiple mice
Oral gavage
(200 uL/day)
Daily for 3 days
beginning on day
after 5-FU (day 9–11)
Microbial diver (alpha
and beta)
5-FU and ampicillin caused a
decrease in microbial diversity,
remaining signiﬁcant for 1
week; mice that received FMT






Case series; N= 2
Patient 1: 50-year old,









Patient 2: 78-year old









donor; stool collected at 3
separate time points and
pooled
Stringent donor screening
based on exclusion of blood-
and stool-based pathogens and
relevant medical conditions.
Clear summary of exclusion
criteria can be found in the
supplementary ﬁles of the
original publication.
150 g stool, processed within
4 h of passage; diluted 1:10 in
0.85% NaCl; prepared using
Stomacher80 Master and
ﬁltered through gauze; stored











Patient 1: complete resolution,





improvement, indicated by a
reduction in CD+ T cells and
concomitant increase in CD4+
FOXp3+.
Patient 2: Partial improvement




In both patients, the number of
















FMT during allo-SCT for
multi-drug resistant
bacteria colonization.
All patients were on
immunosuppressive
medication.
Healthy related or unrelated
donors aged between 18 and
65 with no digestive disorders
within 3 months of donation,
no chronic disease or
treatments, no antibiotics in
the past 3 months. Donors
were also excluded if they
lived in the tropics, or had been
hospitalised abroad for N24 h





Minimum of 50 g of stool was
prepared within 6 h of
collection.
50–100 g stool mixed with
300 mL 0.9% glycerol/saline,
ﬁltered through gauze. Stored
at -80oC.
In some cases (N= 2), fresh
stool was used with
preparation occurring within









Degree of deco ation
- Major: 3 cons ive negative
microbial cultu




achieved in 7/10 patients;
persistent colonization was
achieved in 6/10 patients
Failure occurred in three
patients:
- Unable to cease antibiotics
- Difﬁculties positioning
nasogastroric tube, and unable
to retain enema
- Insufﬁcient stool load (43 g)





GvHD Case series; N= 4
Adult patients with steroid
resistant (N= 3) or
steroid-dependent (N=
1) gastrointestinal acute
Related donor aged 20–64
years; no tattoos/piercings, no
sexual intercourse with a new
partner for 3 months, no blood
transfusion for 3 months, no
Fresh, collected on day of
donation; store day 4oC
under anaerobic conditions
until preparation.




offered a second FMT
Efﬁcacy: gut Gv grade
(assessed using idated
criteria)
- Complete res e:
resolution of al estinal signs
FMT was effective in all
patients, with complete
response in 3/4 patients and





























Indication Study type and
description









travel to tropical areas in 3
months, no antibiotics in last
month, no history of
malignancy or inﬂammatory
bowel disease, no abdominal
symptomology on day of
donation. All samples were
screened for transmissible
diseases.
200–300 mL sterile saline was
added to fecal sample (weight
unknown); fecal slurry was
ﬁltered through sterile metal
sieve and leached through
gauze. Sample was prepared
under ambient conditions.
between 4 and 14
days after the ﬁrst at
the discretion of the
physician.
and symptoms
- Partial response: decrease in
severity of gut GvHD by
minimum of one stage
- Progression: worsened gut
GvHD symptoms
- No change: no signiﬁcant
change in gut GvHD
FMT was considered effective if
the patient achieved CR or PR
in steroid-resistant cases, or a
reduction of ≥40% in the dose
of steroid in steroid-dependent
cases.
Safety: Adverse events that
ﬁrst occurred or progressed
within 1 week of infusion.
Adverse events were largely
mild and transient; the
possibility of an association
between FMT and some
adverse events could not be
completely ruled out.
Case report; N= 1
21-year old female with
acute, stage III, steroid
refractory gastrointestinal
GvHD,
Related donor (sister); no
tattoos/piercings, no sexual
intercourse with a new partner
for 3 months, no blood
transfusion for 3 months, no
travel to tropical areas in 3
months, no antibiotics in last
month, no history of
malignancy or inﬂammatory
bowel disease, no abdominal
symptomology on day of
donation. All samples were
screened for transmissible
diseases.
71–144 g donated feces were
homogenised with sterile
saline; fecal suspension as
passed through a metal sieve
and ﬁltered through sterile
gauze; sample was
centrifuged to isolate
microbial pellet which was
resuspended in 10%
glycerol/saline.
450 uL concentrate was
encapsulated into a #1
hypomellose capsule and
rapidly frozen in liquid
nitrogen; stored at -80oC.
Capsules 15 capsules per day
on days 125, 130, 133
and 144 after
transplantation,
followed by a second
round of FMT on days
173, 181 and 189.





that of the donor, increasing in
diversity with a high
abundance of Lactobacillus.
Enterococcus re-emerged at 4
weeks, and the participant was
offered another FMT.
Second FMT resulted in partial
resolution of symptoms,
decreasing to grade I GvHD.
Kaito et al.
[51]
Feasibility study; N= 8






Donor FMT prepared from N =




40–50 mL of frozen fecal
microbiota resuspended in
200 mL of warm saline.
No further information
provided on preparation.
Nasogastric tube Once Efﬁcacy: severity of GvHD
symptoms (abdominal pain,
diarrhea, presence of bloody
purulent stools); clinical
remission deﬁned if diarrhea
and intestinal spasms and/or
bleeding disappeared, or stool
volume decreased by 500 mL
in 3 days.
Safety: presentation of adverse
events during FMT procedure
or at follow up.




the FMT. At second follow up,
4/8 patients maintained full
cure and 1/8 remained in
remission. Improvements in
GvHD symptoms seen in 1/8
patients. 2/8 patients relapsed
at follow-up.
No adverse events were
reported. Progression free
survival was enhanced in FMT
recipients compared to
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IBD [1,53]. Large, randomized control trials are now required to conﬁrm
safety and efﬁcacy and reﬁne FMT protocols in children.
Beyond the use of FMT in treating CDI and in an adjunctive oncolog-
ical setting, there remains a clear opportunity for FMT in pediatric on-
cology that is yet to be exploited. Survivors of childhood cancer are at
an increased risk of developing late effects and chronic disease
[54–57]. This is becoming an increasingly clear public health problem,
with the large majority (N80%) of children now surviving their diagno-
sis. Recent evidence now indicates that the microbiota of these survi-
vors of childhood cancer (SCC) is not only disrupted acutely during
treatment [58], but also chronically with altered microbiome composi-
tions detected months to years after the cessation of treatment [59]. It
has therefore been hypothesized that residual microbial deﬁciencies
may drive the heightened risk of chronic disease, and as such, efforts
to restore microbial health after treatment may act to mitigate longer-
term microbiome-related diseases.
6. Adjunctive FMT in supportive oncology: how should it look?
6.1. Practical considerations
As outlined, there are a number of relevant applications for FMT in
supportive oncology, with several currently under investigation across
various institutions. Synonymous with the FMT ﬁeld is the degree of
variation in study protocols and trial designs, begging the question of
how should we approach FMT as a supportive adjunct to traditional
anti-cancer therapy?
When designing FMT trials in supportive oncology, there are a num-
ber of important considerations. Stringent donor selection and screen-
ing is important to prevent disease transmission and the FMT delivery
methods may need to be adapted to suit the patient population.
These measures are of particular importance to patient groups who
are heavily immunosuppressed or have comorbidities or treatment-
related complications.
Autologous FMT presents as an attractive option in the adjunctive
oncological setting, however processes around stool collection and de-
livery need to be reﬁned and optimised in the clinical trial setting
(Fig. 3). Whilst autologous FMT may be preferable due to a lower risk
of disease transmission, there may be risks associated with reintroduc-
tion of malignancy (in the case of colorectal cancers) or transmission of
a microbiome that drives carcinogenesis. Feasibility of autologous FMT
must also be carefully considered ensuring there is sufﬁcient time to
collect, prepare and screen the patient's stool between diagnosis and
administration of anticancer therapy. Risks associated with route ofFig. 2. Proposed mechanistic framework for autologous FMT in the therapeutic managemen
therapeutically following allo-SCT may enhance microbial diversity, thus serving to enhanc
microbiome may also promote immune tolerance and dampen inﬂammatory signaling, thus
risk of transmissible diseases, implementation of appropriate criteria may be warranted to e
superdonor may be warranted.administration are also important to consider in the context of support-
ive oncology, with bowel preparation and colonoscopy contraindicated
in patients with a friable bowel. Upper GI delivery is also challenging in
oncology patients where oral mucositis may compromise oral mobility
and the risk of upper GI injury. As such, rectal enemas or oral capsules
represent as sensible options, providing greater ﬂexibility to outpa-
tients. Whilst the large majority of FMT trials continue to administer
fecal slurries via colonoscopy or upper GI delivery, the efﬁcacy of oral
capsules is increasingly demonstrated. Of particular relevance was the
landmark study demonstrating that route of delivery (enema vs oral
capsule containing lyophilized fecal microbiota from 100 to 200 g) did
not inﬂuence adverse experiences from FMT and showed comparable
efﬁcacy in treating CDI in preliminary investigations [60]. Similarly,
third-party FMT prepared as oral capsules was shown to be feasible,
safe and associatedwith an expansion of recipientmicrobiome diversity
in allo-SCT recipients (N=27) [61]. These studies highlight the theoret-
ical merit of deliverying FMT via oral capsule, an approach which has
great potential in theﬁeld of supportive oncologywhich is often compli-
cated by numerous factors. Oral capsules provide ﬂexibility for out-
patients and overcome contraindications in many oncology cohorts.
However, it must be noted that the number of capsules required to
achieve an appropriate microbial load is substantial, with both studies
requiring participants to take over 30 capsules for one FMTdose.Within
supportive oncology where the goal may be to maintain microbial di-
versity over a long time period, rather than restore or change its compo-
sition, encapsulate FMT may be undermined by issues relating to
compliance and the amount of stool required to prepare the appropriate
number of capsules per patient.
The delivery of FMTwithin supportive oncology also remains a chal-
lenge given the lack of gastroenterology expertise amongst clinical care
teams supporting people with cancer. FMT in the oncological setting
would be best implemented in a centre equippedwith the necessary ex-
pertise and facilities [1]. FMT for oncology patients should ideally be
discussedwithin amultidisciplinary team (MDT) to guide patient selec-
tion and preparation as well as appropriate monitoring and follow-up.
An FMTMDT should include oncologists, gastroenterologists, and infec-
tious disease physicians, along with involved nursing and allied health
staff [62]. As suggested by Grover et al., (2016), this team would also
likely beneﬁt from inclusion of a specialised oncogastroenterologist,
with supportive care expertise [63].
6.2. Regulatory considerations
Currently, there is no global common standpoint regarding the reg-
ulatory status of FMT, with one important problem being how FMT ist of acute gastrointestinal toxicity and paralleled prophylaxis of GvHD. FMT delivered
e natural defenses to bacterial translocation and mucosal injury. Restoring an injured
mitigating GvHD development. Whilst autologous FMT is preferential due to the lower
nsure suitable response. Alternatively, donor FMT prepared from a healthy relative or a
738 H.R. Wardill et al. / EBioMedicine 44 (2019) 730–740deﬁned. The difﬁculty in characterising fecalmaterialmeans it has alter-
natively been described as a ‘drug’, ‘biologic’ or ‘transplant’ [64]. Awork-
ing group comprised via the National Institutes of Allergies and
Infectious Diseases proposed the following deﬁnition for regulatory
purposes in 2017: “a microbiota transplantation is the transfer of bio-
logic material containing a minimally manipulated community of mi-
croorganisms from a human donor to a human recipient (including
autologous use) with the intent of affecting the microbiota of the recip-
ient” [65].
Since the landmark clinical FMT trial for recurrent CDI [4], regula-
tions surrounding FMT have undergone many changes worldwide
(Table 3), particularly reﬂected in the USA. The US Food and Drug Ad-
ministration (FDA), began by announcing that FMT would be classiﬁed
as an investigational drug, requiring an Investigational New Drug
(IND) application to be submitted for each FMT use [66]. The IND pro-
cess is effort and resource intensive and as such, there was an immedi-
ate outcry suggesting that this regulation would severely restrict access
to a highly effective treatment [64]. Additionally, there was concern
about the unintended side-effect of increasing risks from at-home
FMT procedures [66]. The FDA responded shortly after by announcing
they would exercise enforcement discretion so IND applications would
not be required for CDI that had not responded to standard treatments,
but would still be required for any other use of FMT [67].
The current regulation of FMT as a drug or live biotherapeutic prod-
uct has had a signiﬁcant impact on the ability to deploy this intervention
in oncological studies in the USA due to the long and difﬁcult IND pro-
cess. Additionally, the majority of regulatory frameworks in place
focus on recurrent CDI, with little consideration for other indications
of FMT.
Finally, there is a need for any regulations to be ﬂexible and graded
to cater for future developments in the ﬁeld such as puriﬁed or live
biotherapeutic products. There are a vast range of new products
currently in development and in clinical trials, and include selectedFig. 3. Practical considerations for implementing autologous sbacterial strains cultured and administered as a capsule, cryopreserved
ﬁltered stool products and lyophilised powders that can be
reconstituted [65]. These products have a different risk proﬁle and
could be produced at industry scales. A proposed regulation framework
recently released is careful to be broad enough to include these products
[68].7. Conclusions
FMT is a highly effective therapy for recurrent and refractory CDI.
Limited available evidence supports the notion that it is a safe therapy
in immunocompetent individuals, however further studies are required.
There are a number of possible applications of FMT in supportive oncol-
ogy, with the potential to manage acute treatment-toxicities and pre-
vent secondary complications of therapy. Efforts should now be
directed at determining the feasibility and safety of FMT as an adjunc-
tive supportive care intervention in both pediatric and adult patients
undergoing cancer therapy.8. Search strategy and selection criteria
Data for this review were identiﬁed by searches on PubMed and
Web of Science. We reviewed the current evidence for FMT in oncology
cohorts with particular focus on its use in immunocompromised co-
horts. (Fecal microbi* transplant*) AND (immunocompromised host
[MeSH]) AND (safety OR adverse event) were used to identify key,
English-language publications, with no restrictions on publication
dates. Meta-analyses and clinical guidelines were priortised. All levels
of evidence were considered, including case studies, with appropriate
acknowledgement of study limitations highlighted throughout the
review.tool banking and FMT into supportive oncology practices.
Table 3
Current and potential international regulatory frameworks for the administration of FMT.
Region Current Framework Future directions Reference
USA The US Food and Drug Administration (FDA) classiﬁed FMT as an
investigational drug, requiring an Investigational New Drug (IND)
application for each FMT use. Outcry due to resource intensive IND
process. The FDA responded shortly after by announcing they would
exercise enforcement discretion so IND applications would not be
required for CDI that had not responded to standard treatments, but
would still be required for any other use of FMT.
Draft guidance under public consultation: stool banks would require
IND to obtain and distribute stool, but not required for physicians
performing the procedure or for hospital laboratories. Classiﬁcation
of FMT as a drug (a live biotherapeutic product) requires thorough
characterization and composition consistency for approval-
infeasible for FMT.
Verbeke et al. [66]
FDA guidance
documents [67,70]
UK Must be manufactured in accordance with Medicines and Healthcare
products Regulatory Agency (MHRA) guidance for human medicines
regulation. Pharmacy exemption possible for single organisation use.
FMT not currently recommended for anything apart from CDI (citing
insufﬁcient evidence).
Consensus for FMT multidisciplinary team to be formed.
Recommend that FMT should be “offered with caution to
immunosuppressed patients, in whom FMT appears efﬁcacious
without signiﬁcant additional adverse effects”
Mullish et al. [71]
Europe Framework varies between countries. European Commission deter-
mined fecal transplant does not constitute a cell/tissue transplant.
Subsequently argued that individual European Union Member States
are free to regulate fecal microbiota transplantation on a national
level.
Consensus document suggest Appropriate FMT registries should be
implemented, in order to collect data concerning indications,
procedure, effectiveness and safety proﬁles., Speciﬁc national rules
for the classiﬁcation of
FMT should be followed to implement an FMT centre.
Cammarota et al. [1]
Australia FMT in local care setting can be delivered - no agreed standards. FMT
material meets the deﬁnition of a biological (contains human
cells/tissues) - prohibits distribution unless Good Manufacturing
Practice (GMP) certiﬁed.
Public consultation currently occurring. Potential transition period
to allow manufacturers and suppliers of FMT to GMP licensing





Costello and Bryant [73]
China Ten hospitals conducting FMT research and administration. Currently,
no standardisation of FMT process and implementation. Consensus
on standardized biobanking of samples has been recently reached.
FMT consensus expert group existing since 2016. Draft consensus
for screening and ethics to soon be published. Recommendation for
a uniﬁed FMT registration system.
Shi et al. [74]
739H.R. Wardill et al. / EBioMedicine 44 (2019) 730–7409. Outstanding questions
There is a clear scientiﬁc and clinical rationale for FMT in the preven-
tion andmanagement of complications of cancer therapy, as well as the
modulation of treatment efﬁcacy. Despite the most recent data indicat-
ing FMT is safe in immunocompromised individuals, there remains a
paucity of data for those that are severely immunocompromised, and
as such, more robust data sets are now required to draw appropriate
conclusions.
Implementation of FMT within oncology requires feasible FMT pro-
tocols to be integrated into the complex treatment schedules of people
undergoing cancer therapy, particularly for applications in which autol-
ogous FMT is preferential. Furthermore, the durability of FMT during cy-
totoxic treatment is unclear, particularly given the widespread use of
prophylactic antibiotics in many oncological cohorts. Future research
should focus on reﬁning FMT protocols for applications in oncology,
with particular focus on the collection, screening and preparation of pa-
tient fecal material. Mode of deliverymust also be appropriately reﬁned
in this patient population given complicating factors including oral mu-
cositis (limiting oral uptake and mobility for FMT capsules), inability to
perform bowel preparations for colonoscopy and the challenges sur-
rounding FMT delivery in the out-patient setting. In cases where FMT
may be used tomodulate response rates to immunotherapies, future re-
search should focus on deﬁning the microbial composition that pro-
motes optimal treatment response. Potential risks associated with
transfer of circulating malignant cells, or microbial phenotypes that
drive carcinogenesis, should also be identiﬁed/eliminated.Acknowledgements
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